In general, AML patients with an NPM1 mutation in the absence of FLT3-ITD belong to the favorable prognostic risk category (ELN 2022 risk stratification for patients receiving intensive treatments) [31]. The gene discussed is FLT3; the disease is acute myeloid leukemia.